New Resmed (ASX:RMD) product could shake up market share – Expert

A new product launch from Resmed has this fund manager excited for its future potential…

| More on:
Medical professionals cheering good news. pro medicus

Image source: Getty Images

Shares in Resmed Inc. (ASX: RMD) are back in focus as the company readies to report tomorrow (ASX Reporting Calendar). Investors are showing eagerness with the share price 1.1% higher to $36.72 in afternoon trade.

Investors are still waiting with bated breath to hear more about the company’s latest sleep apnoea product. The team at Alphinity Investment Management believes the Resmed AirSense 11 could act as a major catalyst for the company.

Could this push the Resmed share price higher?

The Alphinity Australian Share Fund is a diversified portfolio of 35 to 55 stocks selected based on quantitative and fundamental analysis. The fund has delivered investors a net return of 28.4% over the past year. This was roughly in line with the S&P/ASX 300 Accumulation Index return of 28.5%. One of those companies is ASX healthcare titan, Resmed.

In its June quarterly report, Sydney-based boutique investment manager recapped the performance of its Australian Share Fund. On top of that, the fund manager put forward its outlook for the portfolio.

The Alphinity team shared an optimistic perspective towards Resmed, stating:

Resmed has had some challenges with the lagged impact on demand for its sleep apnea products due to a decline in sleep diagnostics during Covid. Testing is now recovering and a significant global product recall by its major global competitor, coinciding with Resmed’s launch of its new S11 airflow generator, is also providing the company with an opportunity for a step-change in market share globally.

The competitor mentioned by the fund manager is Philips. Collectively, ASX-listed Resmed and Philips cater to 90% of the global obstructive sleep apnoea (OSA) devices market and 85% of global OSA markets.

As a result of the 3 to 4 million Philips device recall, Alphinity considers the current landscape to be a considerable opportunity for Resmed. The release date of the healthcare company’s AirSense 11 is yet to be announced, however, it will likely be brought forward.

Are ASX investors sleeping on Resmed?

While the sleep apnoea company took a hit from COVID last year, the fund manager anticipates a recovery in the market. Additionally, the Philips recall opens the gate wide for Resmed to capitalise on expanding market share.

Admittedly, the Resmed share price trading on a price-to-earnings (P/E) ratio may seem expensive. However, the fund believes the market is underestimating the potential earnings upside for the business. ASX-listed Resmed is up 27.9% over the past year.

Lastly, don’t forget to check back tomorrow for its Q4 FY21 results.

Should you invest $1,000 in Resmed right now?

Before you consider Resmed, you'll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now... and Resmed wasn't one of them.

The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

*Returns as of August 16th 2021

Motley Fool contributor Mitchell Lawler has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has recommended ResMed. The Motley Fool Australia has recommended ResMed Inc. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares